| Drug General Information |
| Drug ID |
D0S8CI
|
| Former ID |
DNC011295
|
| Drug Name |
ELIPRODIL
|
| Drug Type |
Small molecular drug
|
| Indication |
Multiple scierosis [ICD9: 340; ICD10:G35]
|
Phase 2 |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C20H23ClFNO
|
| Canonical SMILES |
C1CN(CCC1CC2=CC=C(C=C2)F)CC(C3=CC=C(C=C3)Cl)O
|
| InChI |
1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2
|
| InChIKey |
GGUSQTSTQSHJAH-UHFFFAOYSA-N
|
| CAS Number |
CAS 119431-25-3
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
NMDA receptor subunit NR1 |
Target Info |
Inhibitor |
[2]
|
|---|
| Glutamate [NMDA] receptor subunit epsilon 2 |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Circadian entrainment
|
|
Long-term potentiation
|
|
Glutamatergic synapse
|
|
Alzheimer's disease
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Huntington's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Nicotine addiction
|
|
Alcoholismhsa04014:Ras signaling pathway
|
|
Dopaminergic synapse
|
|
Alcoholism
|
|
Systemic lupus erythematosus
|
|
PANTHER Pathway
|
Huntington disease
|
|
Ionotropic glutamate receptor pathway
|
|
Metabotropic glutamate receptor group III pathway
|
|
Metabotropic glutamate receptor group I pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00029:Huntington disease
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
Pathway Interaction Database
|
ErbB4 signaling events
|
|
Reelin signaling pathway
|
|
Reactome
|
EPHB-mediated forward signaling
|
|
Unblocking of NMDA receptor, glutamate binding and activation
|
|
CREB phosphorylation through the activation of CaMKII
|
|
Ras activation uopn Ca2+ infux through NMDA receptor
|
|
RAF/MAP kinase cascadeR-HSA-3928662:EPHB-mediated forward signaling
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Hypothetical Network for Drug Addiction
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
Spinal Cord Injury
|
|
BDNF signaling pathway
|
|
Alzheimers DiseaseWP666:Hypothetical Network for Drug Addiction
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00001929) Treatment of Parkinson's Disease With Eliprodil. U.S. National Institutes of Health. |
|---|
| REF 2 | J Med Chem. 1999 Jul 29;42(15):2993-3000.4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. |
|---|
